EGFR and melanoma: For this study, LASSBio-1971 was selected from the LASSBio® laboratory’s chemical library to be used as a prototype developed as an irreversible EGFR inhibitor, with proven potency in melanoma, breast, pancreatic tumors, and glioblastoma cell lines [18].